Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15383829 | 0.79 | HCRTR2 (0.32) | HCRTR2HCRTR1 | |
| SCHEMBL16129976 | 0.79 | HCRTR2 (0.32) | HCRTR2HCRTR1 | |
| SCHEMBL805860 | 0.73 | — | — | |
| SCHEMBL30784195 | 0.70 | HCRTR2 (0.40) | HCRTR2HCRTR1 | |
| SCHEMBL21957937 | 0.70 | HCRTR2 (0.40) | HCRTR2HCRTR1 | |
| SCHEMBL31538129 | 0.70 | ALDH1A1 (0.34) | HCRTR2HCRTR1 | |
| SCHEMBL15309131 | 0.69 | LTA4H (0.32) | — | |
| SCHEMBL2939462 | 0.69 | HTR1A (0.35) | HCRTR2HCRTR1 | |
| SCHEMBL16129978 | 0.69 | MAPT (0.53) | AR | |
| SCHEMBL805863 | 0.69 | MAPT (0.53) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895550-B2 | Triazolopyridine compounds as PIM kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140045835-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8557809-B2 | Triazolopyridine compounds as PIM kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20110144100-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-16 | — | — | US | disclosed |
| WO-2010022081-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045835-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | BACE1 4088/4885AR 3323/4885HCRTR2 4289/4885 |
| US-20110144100-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | PIM1, PIM3, PIM2 | BACE1 3846/4885AR 2330/4885HCRTR2 3505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.